Antihelminthic niclosamide modulates dendritic cells activation and function

Cellular Immunology

Volumn 288, Issue 1-2, 2014, Pages 15-23

  Wu, Chieh Shan ^a,b   Li, Yi Rong ^c   Chen, Jeremy J W ^c   Chen, Ying Che ^c   Chu, Chiang Liang ^d   Pan, I Hong ^e   Wu, Yu Shan ^f   Lin, Chi Chen ^c,g,h  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^f TUNGHAI UNIVERSITY   (Taiwan)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Contact hypersensitivity (CHS); Cytokine; Dendritic cells; Niclosamide; T cell proliferation

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NICLOSAMIDE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELLULAR IMMUNITY; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SENSITIZATION; FEMALE; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED CELL CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

CONTACT HYPERSENSITIVITY (CHS); CYTOKINE; DENDRITIC CELLS; NICLOSAMIDE; T CELL PROLIFERATION;

ANIMALS; ANTHELMINTICS; BONE MARROW CELLS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; DINITROFLUOROBENZENE; FEMALE; GENE EXPRESSION REGULATION; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOMODULATION; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; NICLOSAMIDE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84896505684     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.12.006     Document Type: Article

References (51)

1. Hivroz C., Chemin K., Tourret M., Bohineust A. Crosstalk between T lymphocytes and dendritic cells. Crit. Rev. Immunol. 2012, 32(2):139-155.
2. Watts C., West M.A., Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22(1):124-130.
3. Förster R., Braun A., Worbs T. Lymph node homing of T cells and dendritic cells via afferent lymphatics. Trends Immunol. 2012, 33(6):271-280.
4. Yanagawa Y., Iijima N., Iwabuchi K., Ono'e K. Activation of extracellular signal-related kinase by TNF-α controls the maturation and function of murine dendritic cells. J. Leukoc. Biol. 2002, 71(1):125-132.
5. Hubert P., Jacobs N., Caberg J.H., Boniver J., Delvenne P. The cross-talk between dendritic and regulatory T cells: good or evil?. J. Leukoc. Biol. 2007, 82(4):781-794.
6. Morel P.A., Turner M.S. Dendritic cells and the maintenance of self-tolerance. Immunol. Res. 2011, 50(2-3):124-129.
7. Jolivel V., Luessi F., Masri J., et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013, 136(Pt. 4):1048-1066.
8. Frikeche J., Simon T., Brissot E., Grégoire M., Gaugler B., Mohty M. Impact of valproic acid on dendritic cells function. Immunobiology 2012, 217(7):704-710.
9. Frikeche J., Peric Z., Brissot E., Grégoire M., Gaugler B., Mohty M. Impact of HDAC inhibitors on dendritic cell functions. Exp. Hematol. 2012, 40(10):783-791.
10. Kirsch B.M., Zeyda M., Stuhlmeier K., et al. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res. Ther. 2005, 7(3):R694-R703.
11. Wang Z.Y., Morinobu A., Kawano S., Saegusa J., Wang B., Kumagai S. Gold sodium thiomalate suppresses the differentiation and function of human dendritic cells from peripheral blood monocytes. Clin. Exp. Rheumatol. 2002, 20(5):683-688.
12. Elftman M.D., Norbury C.C., Bonneau R.H., Truckenmiller M.E. Corticosterone impairs dendritic cell maturation and function. Immunology 2007, 12(2):279-290.
13. Dimasi J.A. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. Clin. Ther. 2013, 35(6):808-818.
14. Trotta F., Leufkens H.G., Schellens J.H., Laing R., Tafuri G. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J. Clin. Oncol. 2011, 29(16):2266-2272.
15. Ditzel J., Schwartz M. Worm cure without tears. The effect of niclosamide on taeniasis saginata in man. Acta Med. Scand. 1967, 182(5):663-664.
16. Pampori N.A., Singh G., Srivastava V.M. Energy metabolism in Cotugnia digonopora and the effect of anthelmintics. Mol. Biochem. Parasitol. 1984, 11:205-213.
17. Lu W., Lin C., Roberts M.J., Waud W.R., Piazza G.A., Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS ONE 2011, 6(12):e29290.
18. Osada T., Chen M., Yang X.Y., et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011, 71(12):4172-4182.
19. Jin Y., Lu Z., Ding K., et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010, 70(6):2516-2527.
20. Ren X.M., Duan L., He Q., et al. Identification of niclosamide as a new small molecule inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett. 2010, 1(9):454-459.
21. Balgi A.D., Fonseca B.D., Donohue E., et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS ONE 2009, 4(9):e7124.
22. Fonseca B.D., Diering G.H., Bidinosti M.A., et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 2012, 287(21):17530-17545.
23. Wang A.M., Ku H.H., Liang Y.C., Chen Y.C., Hwu Y.M., Yeh T.S. The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J. Cell. Biochem. 2009, 106(4):682-692.
24. Chen D.Y., Song P.S., Hong J.S., et al. Dextromethorphan inhibits activations and functions in dendritic cells. Clin. Dev. Immunol. 2013, 2013:125643.
25. Wang S.T., Chang C.C., Yen M.C., et al. RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency. Gene Ther. 2011, 18(4):372-383.
26. Huang R.Y., Yu Y.L., Cheng W.C., OuYang C.N., Fu E., Chu C.L. Immunosuppressive effect of quercetin on dendritic cell activation and function. J. Immunol. 2010, 184(12):6815-6821.
27. Kim G.Y., Han M.G., Song Y.S., et al. Proteoglycan isolated from Phellinus linteus induces toll-like receptors 2- and 4- mediated maturation of murine dendritic cells via activation of ERK, p38, and NFκB. Biol. Pharm. Bull. 2004, 27(10):1656-1662.
28. Rescigno M., Martino M., Sutherland C.L., Gold M.R., Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 1998, 188(11):2175-2180.
29. Yokoi S., Niizeki H., Iida H., Asada H., Miyagawa S. Adjuvant effect of lipopolysaccharide on the induction of contact hypersensitivity to haptens in mice. J. Dermatol. Sci. 2009, 53(2):120-128.
30. Wu C.J., Jan J.T., Chen C.M., et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 2004, 4(7):2693-2696.
31. Imperi F., Massai F., Ramachandran Pillai C., et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob. Agents Chemother. 2013, 57(2):996-1005.
32. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008, 19(1):41-52.
33. Prevosto C., Goodall J.C., Hill Gaston J.S. Cytokine secretion by pathogen recognition receptor-stimulated dendritic cells in rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 2012, 39(10):1918-1928.
34. Mizutani H., Ohmoto Y., Mizutani T., Murata M., Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J. Dermatol. Sci. 1997, 14(2):145-153.
35. Bellanti J.A. Cytokines and allergic diseases: clinical aspects. Allergy Asthma Proc. 1998, 19(6):337-341.
36. Silva L.C., Ortigosa L.C., Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010, 2(6):817-833.
37. Mihara M., Nishimoto N., Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin. Biol. Ther. 2005, 5(5):683-690.
38. Gately M.K., Renzetti L.M., Magram J., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 1998, 16:495-521.
39. Hirschfeld M., Weis J.J., Toshchakov V., et al. Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 2001, 69(3):1477-1482.
40. Wang J.Y. The innate immune response in house dust mite-induced allergic inflammation. Allergy Asthma Immunol. Res. 2013, 5(2):68-74.
41. Gasparini C., Feldmann M. NF-κB as a target for modulating inflammatory responses. Curr. Pharm. Des. 2012, 18(35):735-5745.
42. Wang J., Wang X., Hussain S., et al. Distinct roles of different NF-kappa B subunits in regulating inflammatory and T cell stimulatory gene expression in dendritic cells. J. Immunol. 2007, 178(11):6777-6788.
43. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11(5):373-384.
44. Merschjohann K., Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide. Exp. Parasitol. 2008, 118(4):637-640.
45. WHO, 2002. WHO specifications and evaluations for public health pesticides: niclosamide. World Health Organisation, Geneva. Available from: http://www.who.int/whopes/quality/en/Niclosamide.pdf.
46. Chang Y.W., Yeh T.K., Lin K.T., Chen W.C., Yao H.T., Lan S.J., et al. Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats. J. Food Drug Anal. 2006, 14:329-333.
47. Krawczyk C.M., Holowka T., Sun J., Blagih J., Amiel E., DeBerardinis R.J., et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010, 115(23):4742-4749.
48. Pearson R.D., Hewlett E.L. Niclosamide therapy for tapeworm infections. Ann. Intern. Med. 1985, 102(4):550-551.
49. Jurgeit A., McDowell R., Moese S., Meldrum E., Schwendener R., Greber U.F. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012, 8(10):e1002976.
50. McCullough K.C., Ruggli N., Summerfield A. Dendritic cells-at the front-line of pathogen attack. Vet. Immunol. Immunopathol. 2009, 128(1-3):7-15.
51. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208(10):1989-2003.